PJB-2021-654
In Vitro study of Thrombolytic activity from the different parts of Carica papaya plant on COVID-19 patients.
Ayesha afzal
Abstract
Background: Various types of plants can be used in herbalism and exhibit medicinal properties. Plants can be used in the synthesis and development of drugs. Carica papaya plant has been used for medicinal purpose throughout the world because Carica papaya showed many activities, like anti-inflammatory, anti-oxidant, antiviral, anti-cancer and wound healing etc. The current research project has been designed to study the thrombolytic activity of Carica papaya plant. Objective: The main object of this research was to evaluate the thrombolytic activity of Carica papaya plant in normal healthy individuals and COVID-19 patients to determine either parts of the plant (roots, seeds and leaves) exhibit more activity in normal persons or in patients. Material and method: For this study, total 20 blood samples were taken, 10 for normal individuals and 10 for positive COVID-19 patients. We used two different solvents i.e. autoclaved distilled water and concentrated methanol to prepare the 10% root, seed and leaf extracts of Carica papaya plant. For the thrombolytic activity of these plant extracts, samples were arranged as a triplicate for the accuracy of results percentage. Results: Our results evaluated that in normal individuals, distilled water root extract and methanolic seed extract exhibits maximum thrombolytic activity. The mean value with distilled water (root extract) and methanol (seed extract) is 36.9% and 32.9% respectively. While in covid-19 patients, distilled water leaf extract and methanolic leaf extract reveal maximum thrombolytic activity. In patients, the mean value with distilled water and methanol (leaf extract) is 21.8% and 23% respectively. P-value (<0.05) considered as statistically significant. Conclusion: In our study, we have observed that normal persons showed highly significant results as compared to COVID-19 patients. Because in COVID-19 disease, plasminogen activator inhibitor 1 (PAI-1), thrombin activatable fibrinolysis inhibitor (TAFI) and tissue plasminogen activator (tPA) factors elevate which results in hypo-fibrinolysis.
To Cite this article:
Download
